Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Does the addition of trastuzumab to ACP adjuvant therapy increase the late development of CHF in patients with node-positive, HER2-positive breast cancer?

The addition of trastuzumab to ACP chemotherapy has a favorable risk-benefit profile, with late development of CHF being uncommon at 7-year follow-up.